Placebo News and Research

RSS

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.

22 Feb 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Shionogi today announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with naldemedine significantly improved opioid-induced constipation (OIC) compared to placebo in patients with chronic non-cancer pain.

22 Feb 2016

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy.

19 Feb 2016

FDA-approved Alzheimer's medications may help people quit smoking

Despite several safe drug therapies available to help smokers quit, three-quarters report relapsing within six months of a quit attempt. University of Pennsylvania researchers Rebecca Ashare and Heath Schmidt saw potential for a permanent cessation solution in a class of FDA-approved medications used to improve cognitive impairments from Alzheimer's disease.

19 Feb 2016

Tackling insulin resistance may reduce recurrence after stroke

Giving pioglitazone to stroke survivors with insulin resistance but no overt diabetes reduces their risk of having a recurrent vascular event, shows the randomised Insulin Resistance Intervention after Stroke trial.

18 Feb 2016

More phase II success for CGRP migraine prevention strategy

Another antibody targeting the calcitonin gene-related peptide pathway has proved successful against episodic migraine in a phase II trial.

18 Feb 2016

Testosterone treatment for older men improves sexual function, walking ability and mood

As men age, their testosterone levels decrease, but prior studies of the effects of administering testosterone to older men have been inconclusive. Now, research shows that testosterone treatment for men over 65 improves sexual function, walking ability and mood, according to a study published in the New England Journal of Medicine by team researchers from the Perelman School of Medicine at the University of Pennsylvania, and twelve other medical centers in the United States, in partnership with the National Institute on Aging.

18 Feb 2016

Pioglitazone drug may prevent recurrent stroke and heart attacks

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes.

18 Feb 2016

Promising phase II results for ozanimod in MS

The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing-remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology.

17 Feb 2016

Study: Many school children avoid basic foods due to perceived hypersensitivity

A study on hypersensitivity to the basic foods milk, egg, fish and wheat among young school children showed that reported food hypersensitivity was eight times more common than allergies confirmed by allergy tests. This according to a new dissertation at Umeå University.

17 Feb 2016

Experimental vaccine shows effectiveness in Ebola vaccine trial

An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa -- and the approach could establish a new way of responding to outbreaks of emerging pathogens, including the Zika virus.

16 Feb 2016

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Neurotrope, Inc. today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease.

16 Feb 2016

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

A clinical trial of an experimental drug for treatment-resistant major depression finds that modulation of the endogenous opioid system may improve the effectiveness of drugs that target the action of serotonin and related monoamine neurotransmitters.

12 Feb 2016

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015.

12 Feb 2016

Scientists find that daily dose of beetroot juice significantly improves exercise endurance, blood pressure

Scientists at Wake Forest Baptist Medical Center have found that a daily dose of beetroot juice significantly improved exercise endurance and blood pressure in elderly patients with heart failure with preserved ejection fraction (HFPEF).

11 Feb 2016

Oral therapeutic drug shows promise against recurrent C. difficile infection

Results from a Phase 1b/2 trial suggest that an investigational microbiome-based, oral therapeutic drug is effective for the treatment of recurrent C. difficile infection. In a paper published online in the Journal of Infectious Diseases, a multi-institutional research team reports that treatment with the preparation, containing the spores of approximately 50 species of beneficial bacteria, successfully prevented recurrence of C. difficile infection (CDI) in patients with a history of multiple recurrent disease.

10 Feb 2016

Medical marijuana offers hope for kids with uncontrolled seizures

Desperate for relief, parents are taking unusual steps to help children plagued with seizures. The relief, however, comes in a most unlikely form: marijuana.

9 Feb 2016

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD).

5 Feb 2016

Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Researchers of a new study published in the current issue of Biological Psychiatry report successful reduction of depressive symptoms in patients using a novel non-invasive method of vagus nerve stimulation, or VNS.

5 Feb 2016

Placebo News and Research

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

FDA-approved Alzheimer's medications may help people quit smoking

Tackling insulin resistance may reduce recurrence after stroke

More phase II success for CGRP migraine prevention strategy

Testosterone treatment for older men improves sexual function, walking ability and mood

Pioglitazone drug may prevent recurrent stroke and heart attacks

Promising phase II results for ozanimod in MS

Study: Many school children avoid basic foods due to perceived hypersensitivity

Experimental vaccine shows effectiveness in Ebola vaccine trial

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Scientists find that daily dose of beetroot juice significantly improves exercise endurance, blood pressure

Oral therapeutic drug shows promise against recurrent C. difficile infection

Medical marijuana offers hope for kids with uncontrolled seizures

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News